Overactive bladder. Overactive bladder
Conditions
Interventions
Solifenacin according to the treatment protocol administered orally, 5 milligrams daily with the possibility of increasing to 10 milligrams if clinically needed and tolerated, for a duration of 12 wee
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Muslim woman Clinical diagnosis of overactive bladder (OAB) Age 18 to 75 years Informed consent Ability to complete questionnaires
Exclusion criteria
Exclusion criteria: Pregnancy Active urinary tract infection Neurological diseases affecting bladder function Concurrent use of interacting drugs or other antimuscarinics Intolerance or drug discontinuation due to adverse effects Failure to complete post-treatment assessment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of overactive bladder (OAB) questionnaire scores after treatment compared to baseline values (pre-treatment). Timepoint: Baseline, 4 weeks and 12 weeks after the intervention. Method of measurement: ICIQ-OAB questionnaire.;Comparison of Incontinence Praying Ability (I-PA) questionnaire scores after the intervention compared to baseline values (pre-treatment). Timepoint: Baseline, 4 weeks and 12 weeks after the intervention. Method of measurement: I-PA questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSakineh Hajebrahimi
Tabriz University of Medical Sciences
Outcome results
None listed